Economic and social burden of severe sepsis

Yearbook of Intensive Care and Emergency Medicine 2009

Volumn , Issue , 2007, Pages 129-138

  Silva, E ^a   Araujo, D V ^b  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892059428     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-92278-2_13     Document Type: Chapter

References (35)

1. Angus DC, Pereira CA, Silva E (2006) Epidemiology of severe sepsis around the world. Endocr Metab Immune Disord Drug Targets 6: 207-212
2. Silva E, Pedro MA (2004) Brazilian Sepsis Epidemiological Study (BASES study). Crit Care 8:R251-260
3. Martin G S, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348: 1546-1554
4. Moerer O, Schmid A, Hofmann M, et al (2002) Direct costs of severe sepsis in three German intensive care units based on retrospective electronic patient record analysis of resource use. Intensive Care Med 28: 1440-1446
5. Burchardi H, Schneider H (2004) Economic aspects of severe sepsis. A review of intensive care unit costs, cost of illness and cost effectiveness of therapy. Pharmacoeconomics 22: 793-813
6. Edbrooke D, Hibbert C, Ridley S, Long T, Dickie H (1999) The development of a method for comparative costing of individual intensive care units. Anaesthesia 54: 110-120
7. Lee H, Doig CJ, Ghali WA, Donaldson C, Johnson D, Manns B (2004) Detailed cost analysis of care for survivors of severe sepsis. Crit Care Med 32: 981-985
8. Edbrooke DL, Hibbert CL, Kingsley JM, Smith S, Bright NM, Quinn JM (1999) The patientrelated cost of care for sepsis patients in a United Kingdom adult general intensive care unit. Crit Care Med 27: 1760-1767
9. Angus DC, Linde-Zwirble WT, Lidicker J, et al (2001) Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 29: 1303-1310
10. Brun-Buisson C, Roudot-Thoraval F, Girou E, Grenier-Sennelier C, Durand-Zaleski I (2003) The costs of septic syndromes in the intensive care unit and influence of hospital-acquired sepsis. Intensive Care Med 29: 1464-1471
11. Heyland DK, Kernerman P, Gafni A, Cook DJ (1996) Economic evaluations in the critical care literature: do they help us improve the efficiency of our unit? Crit Care Med 24: 1591-1598
12. American Thoracic Society Workshop on Outcomes Research (2002) Understanding costs and cost-effectiveness in critical care. Am J Respir Crit Care Med 165: 540-550
13. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ (2005) Methods for the Economic Evaluation of Health Care Programmes, 3rd ed. Oxford University Press, Oxford
14. Sefton T, Byford S, McDaid D, Hills J, Knapp M (2002) Making the Most of it: Economic Evaluation in the Social Welfare Field. Joseph Rowntree Foundation, York
15. References to obtain unit costs for pharmaceuticals and health care equipment Joint Formulary Committee. British National Formulary 52. British Medical Association and the Royal Pharmaceutical Society of Great Britain, London
16. Gold MR, Russell LB, Seigel JE, Weinstein MC (1996) Cost-effectiveness in Health and Medicine. Oxford University Press, New York
17. Braun L, Riedel AA, Cooper LM (2004) Severe sepsis in managed care: analysis of incidence, one-year mortality, and associated costs of care. J Manag Care Pharm 10: 521-530
18. Chalfin DB, Holbein ME, Fein AM, Carlon GC (1993) Cost-effectiveness of monoclonal antibodies to gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients. JAMA 269: 549-254
19. Sogayar AM, Machado FR, Rea-Neto A, et al (2008) A multicentre, prospective study to evaluate costs of septic patients in Brazilian intensive care units. Pharmacoeconomics 26: 425-434
20. Cheng B, Xie G, Yao S, et al (2007) Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China. Crit Care Med 35: 2538-2546
21. Schmid A, Burchardi H, Clouth J, Schneider H (2002) Burden of illness imposed by severe sepsis in Germany. Eur J Health Econ 3: 77-82
22. Dellinger, RP, Levy, MM, Carlet, JM, et al (2008) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 34: 17-60
23. Bernard GR, Vincent JL, Laterre PF, et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699-709
24. Abraham E, Laterre PF, Garg R, et al (2005) Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353: 1332-1341
25. Manns BJ, Lee H, Doig CJ, Johnson D, Donaldson C (2002) An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 347: 993-1000
26. Angus DC, Linde-Zwirble WT, Clermont G, et al (2003) Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 31: 1-11
27. Dhainaut JF, Payet S, Vallet B, et al (2007) Cost-effectiveness of activated protein C in real-life clinical practice. Crit Care 11:R99
28. Brar SS, Manns BJ (2007) Activated protein C: cost-effective or costly? Crit Care 11:164
29. Fowler RA, Hill-Popper M, Stasinos J, Petrou C, Sanders GD, Garber AM (2003) Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis. J Crit Care 18: 181-191
30. Neilson AR, Burchardi H, Chinn C, Clouth J, Schneider H, Angus D (2003) Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany. J Crit Care 18: 217-227
31. Betancourt M, McKinnon PS, Massanari RM, Kanji S, Bach D, Devlin JW (2003) An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures. Pharmacoeconomics 21: 1331-1340
32. Shorr AF, Micek ST, Jackson WL Jr, Kollef MH (2007) Economic implications of an evidencebased sepsis protocol: can we improve outcomes and lower costs? Crit Care Med 35: 1257-1262
33. Talmor D, Greenberg D, Howell MD, Lisbon A, Novack V, Shapiro N (2008) The costs and cost-effectiveness of an integrated sepsis treatment protocol. Crit Care Med 36: 1168-1174
34. Rivers E, Nguyen B, Havstad S, et al (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345: 1368-1377
35. Talmor D, Shapiro N, Greenberg D, Stone PW, Neumann PJ (2006) When is critical care medicine cost-effective? A systematic review of the cost-effectiveness literature. Crit Care Med 34: 2738-2747